Economic and clinical impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada

Research Type

Clinical

Abstract Category

Health Services Delivery

Links
	Abstract 564
	Pelvic Pain and Urinary Tract Infection Scientific Podium Short Oral Session 28
	Friday 16th September 2016
	14:52 - 15:00
	Hall B5
	Incontinence Mathematical or statistical modelling Outcomes Research Methods Overactive Bladder
	1. Astellas Pharma Europe Ltd., Chertsey, UK, 2. University of Alberta, Edmonton, Canada, 3. Parexel International, London, UK, 4. Manchester Metropolitan University, Manchester, UK, 5. Astellas Pharma Canada Inc., Markham, Canada, 6. Astellas Pharma Europe B.V., Leiden, the Netherlands
Presenter
A Adrian Wagg University of Alberta, Edmonton, Canada
Abstract PDF Edit Abstract Abstract Centre